MD News and Information

Actelion Stresses Importance of PAH Early Detection, Life Quality at 2016 SSc World Congress and in Exclusive Interview

Author: Patricia Silva
Date Published: February-2016
Source: Scleroderma News

New data was recently presented regarding Actelion Pharmaceuticals’ therapies and strategies to improve clinical outcomes in patients with pulmonary arterial hypertension (PAH). The data were presented at the Actelion Satellite Symposium, titled “Improving outcome in pulmonary arterial hypertension,” which was part of the 4th Systemic Sclerosis World Congress held in Lisbon, Portugal, on Feb. 18-20, 2016.

 

Systemic Sclerosis Mouse Study of Nintedanib in Fibrotic and Vascular Manifestations Looks Promising

Author: Daniela Semedo
Date Published: February-2016
Source: Scleroderma News

Nintedanib (OFEV) seems to inhibit the activation of fibroblasts and to exert an anti-fibrotic effect in mouse models of systemic sclerosis (SSc), according to data recently presented at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, last week. The presentation, “Effects of Nintedanib on Fibrotic and Vascular Manifestation in Pre-clinical Models of Systemic Sclerosis,” was given by J. Distler from the Department of International Medicine 3 and the Institute for Clinical Immunology at the University of Erlangen-Nuremberg in Germany.

 

Typical Therapies Not Tough Enough to Curb Digital Ulcers

Author: Damian McNamara
Date Published: February-2016
Source: Medscape

Patients with systemic sclerosis and a recent history of digital ulcers remain at significantly higher risk of developing a new one, according to an observational study. The findings also suggest a common treatment might be insufficient for prevention in this high-risk subset. The study is one of five observational studies that make up the DeSScipher project, sponsored by the Scleroderma Society in London, United Kingdom.

 

PAH Drug, Opsumit, Seen to Prevent and Treat Lung Disease in a Mouse Model of Scleroderma

Author: Margarida Azevedor
Date Published: February-2016
Source: Pulmonary Hypertension News

Researchers at University College London (UCL) and Actelion Pharmaceuticals presented a study investigating the therapeutic effect of macitentan (Opsumit) in a mouse model of pulmonary hypertension associated with systemic scleroderma (SSc). The presentation, titled “Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with altered TGFbeta/BMPRII Signalling,” took place at the recent 4th Systemic Sclerosis World Congress in Lisbon, Portugal.

 

Leading Researcher: Fibrosis Improved in Systemic Sclerosis and IPF Models With Monoclonal Antibody

Author: Margarida Azevedor
Date Published: February-2016
Source: Scleroderma News

Researchers at ChemomAb and Meir Medical Center in Tel Aviv, Israel, and the University of Florence, Italy, recently presented a study investigating the therapeutic effect of the monoclonal antibody CM-101 in animal models of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). The data was presented last week in a talk titled “CM-101, a Novel Monoclonal Antibody Blocking CCL24 Ameliorates Experimental Systemic Sclerosis (SSc) and Idiopathic Pulmonary Fibrosis (IPF)” at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal. Systemic sclerosis and IPF are two conditions that involve the development and accumulation of fibrotic tissue and progressive decline of the patient’s health status. 

 

Lung Ailment in Systemic Sclerosis More Aggressive in Men -- But survival the same as in women

Author: Wayne Kuznar
Date Published: February-2016
Source: MedPage Today

Although pulmonary arterial hypertension (PAH) is more common in women with systemic sclerosis (SSc), men had a shorter interlude after an SSc diagnosis to the occurrence of PAH, were younger at the time of PAH diagnosis, and had a shorter PAH disease duration, Canadian researchers found.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 21